InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09. September 2021 19:18 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare...
InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference
12. August 2021 12:00 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based...
InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules
02. Juli 2021 16:15 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 02, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based...
InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules
29. Juni 2021 07:00 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based...
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids
29. Juni 2021 07:00 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based...
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production
17. Juni 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
5 g/L cannabinoid yield significantly exceeds reported industry yieldsSignificantly reduces the overall cost of rare cannabinoid manufacturingContinued advancement to GMP-ready large-scale batch...
InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference
09. Juni 2021 11:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based...
InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results
13. Mai 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 13, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM), a clinical-stage company developing pharmaceutical-based drug...
InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results
06. Mai 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based...
InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021
04. Mai 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based...